White coat hypertension in definition of metabolic syndrome
Mehmet Rami Helvaci1, Hasan Kaya, Mahmut Seyhanli
1Medical Faculty of the Mustafa Kemal University, Antakya, Turkey.
Insights
Metabolic syndrome is a reversible stage before irreversible diseases like diabetes and hypertension develop. Including reversible factors like excess weight and white coat hypertension in its definition is crucial for early intervention.
Area of Science:
- Cardiovascular Health
- Metabolic Disorders
- Preventive Medicine
Background:
- White coat hypertension (WCH) is recognized for its health impact, yet lacks a defined role within metabolic syndrome.
- Metabolic syndrome represents a critical, potentially reversible, stage preceding irreversible chronic diseases.
Purpose of the Study:
- To propose an updated definition of metabolic syndrome that incorporates reversible risk factors.
- To differentiate between reversible metabolic disturbances and irreversible end-stage diseases.
Main Methods:
- Analysis of 1068 patients aged 20+ undergoing check-ups.
- Comparative analysis of age-related prevalence trends for various metabolic risk factors and chronic diseases.
Main Results:
- Prevalence of hyperbetalipoproteinemia, hypertriglyceridemia, dyslipidemia, impaired glucose tolerance (IGT), and WCH increased with age until the seventh decade, then decreased.
- Hypertension (HT), diabetes mellitus (DM), and coronary heart disease (CHD) prevalences showed consistent, irreversible increases with age.
- Metabolic syndrome is characterized by reversible factors, contrasting with irreversible conditions like DM, HT, and CHD.
Conclusions:
- Metabolic syndrome should be defined by reversible risk factors (e.g., excess weight, dyslipidemia, WCH, IGT) rather than irreversible diseases.
- Early identification and management of reversible factors are key, as pharmaceutical interventions become less effective after irreversible disease onset.
- Defining metabolic syndrome with reversible components emphasizes its role as a modifiable precursor to severe health outcomes.
Abstract:
Although white coat hypertension (WCH) is believed to have an effect on health, there is no term defining WCH in metabolic syndrome. Consecutive patients 20 years old or older who underwent a check-up were included. The study included 1068 cases. The prevalences of hyperbetalipoproteinemia, hypertriglyceridemia, dyslipidemia, impaired glucose tolerance (IGT), and WCH were similar to excess weight in that they increased significantly until the seventh decade of life and decreased thereafter significantly (P < 0.05 in most steps). On the other hand, the prevalences of hypertension (HT), diabetes mellitus (DM), and coronary heart disease (CHD) always increased significantly with age without any decrease (P < 0.05 in most steps), indicating their irreversibility in contrast to the reversibility of excess weight, hyperbetalipoproteinemia, hypertriglyceridemia, dyslipidemia, IGT, and WCH. Metabolic syndrome is a reversible progression step between health and irreversible final diseases terminating with increased mortality and disabilities. Thus, the definition of metabolic syndrome should include reversible metabolic risk factors such as excess weight (overweight and obesity), hyperbetalipoproteinemia, hypertriglyceridemia, dyslipidemia, IGT, and WCH, instead of irrevesible diseases such as DM, HT, CHD, and stroke that have already developed and require drug therapy. After development of one of the final metabolic diseases, the term metabolic syndrome probably loses most of its significance, since from that point on, nonpharmaceutical approaches such as lifestyle changes, diet, and exercise will provide little benefit to prevent development of the others, most likely due to the cumulative effects of the risk factors on body systems over a long period of time.
More Related Videos
07:51Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
09:40Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
Published on: January 19, 2017
Related Concept Videos
Hypertension I: Introduction
Hyperosmolar Hyperglycemic State
Hypertension III: Clinical Manifestations and Diagnostic Studies
Cushing Syndrome I: Introduction
Hypertension II: Pathophysiology
Coronary Artery Disease I: Introduction
